Shouyao Holdings (Beijing) Co. Ltd. A Net Assets
Shouyao Holdings (Beijing) Co. Ltd. A net assets. Based on the latest financial reports, Shouyao Holdings (Beijing) Co. Ltd. A (688197) has net assets worth CN¥619.12 Million CNY (≈ $90.60 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥725.73 Million ≈ $106.20 Million USD) and total liabilities (CN¥106.61 Million ≈ $15.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Shouyao Holdings (Beijing) Co. Ltd. A net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥619.12 Million |
| % of Total Assets | 85.31% |
| Annual Growth Rate | 25.44% |
| 5-Year Change | 45193.5% |
| 10-Year Change | N/A |
| Growth Volatility | 29917.32 |
Net Assets of Shouyao Holdings (Beijing) Co. Ltd. A (2019–2025)
Net assets of Shouyao Holdings (Beijing) Co. Ltd. A from 2019 to 2025. This chart illustrates how Shouyao Holdings (Beijing) Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See how leveraged is Shouyao Holdings (Beijing) Co. Ltd. A's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Shouyao Holdings (Beijing) Co. Ltd. A (2019–2025)
The table below shows the annual net assets of Shouyao Holdings (Beijing) Co. Ltd. A from 2019 to 2025. For live market cap and overall valuation, see 688197 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥680.18 Million ≈ $99.53 Million |
-15.92% |
| 2024-12-31 | CN¥809.01 Million ≈ $118.38 Million |
-20.76% |
| 2023-12-31 | CN¥1.02 Billion ≈ $149.40 Million |
-15.38% |
| 2022-12-31 | CN¥1.21 Billion ≈ $176.55 Million |
+80243.11% |
| 2021-12-31 | CN¥1.50 Million ≈ $219.75K |
-98.97% |
| 2020-12-31 | CN¥146.42 Million ≈ $21.43 Million |
-16.12% |
| 2019-12-31 | CN¥174.56 Million ≈ $25.54 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shouyao Holdings (Beijing) Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 107110770774.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Shouyao Holdings (Beijing) Co. Ltd. A Net Assets Breakdown (December 2025)
Shouyao Holdings (Beijing) Co. Ltd. A net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥1.83 Billion | 268.56% |
| Total Equity | CN¥680.18 Million | 100.00% |
Shouyao Holdings (Beijing) Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shouyao Holdings (Beijing) Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Yuchai International Limited
NYSE:CYD
|
$750.37 Million |
|
Rayhoo Motor Dies Co Ltd
SHE:002997
|
$750.44 Million |
|
Ningbo Thermal Power Co Ltd
SHG:600982
|
$750.67 Million |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
$750.74 Million |
|
Cablevision Holding SA
BA:CVH
|
$750.14 Million |
|
Safehold Inc
NYSE:SAFE
|
$749.94 Million |
|
Guangzhou Automobile Group Co. Ltd
F:02G
|
$749.92 Million |
|
Zhongzhong Science & Technology (Tianjin) Co. Ltd. A
SHG:603135
|
$749.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shouyao Holdings (Beijing) Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 809,013,113 to 680,178,870, a change of -128,834,243 (-15.9%).
- Net loss of 128,834,243 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-128.83 Million | -18.94% |
| Other Changes | CN¥-0.00 | -0.0% |
| Total Change | CN¥- | -15.92% |
Book Value vs Market Value Analysis
This analysis compares Shouyao Holdings (Beijing) Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 22.12x to 7.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥1.56 | CN¥34.47 | x |
| 2020-12-31 | CN¥1.31 | CN¥34.47 | x |
| 2021-12-31 | CN¥0.01 | CN¥34.47 | x |
| 2022-12-31 | CN¥8.11 | CN¥34.47 | x |
| 2023-12-31 | CN¥6.86 | CN¥34.47 | x |
| 2024-12-31 | CN¥5.44 | CN¥34.47 | x |
| 2025-12-31 | CN¥4.57 | CN¥34.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shouyao Holdings (Beijing) Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1486.39%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.16x
- Recent ROE (-18.94%) is above the historical average (-1425.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -22.78% | -343.00% | 0.05x | 1.26x | CN¥-56.99 Million |
| 2020 | -225.46% | -4703.18% | 0.04x | 1.24x | CN¥-344.76 Million |
| 2021 | -9650.40% | -1112.00% | 0.22x | 38.74x | CN¥-145.07 Million |
| 2022 | -14.41% | -9512.74% | 0.00x | 1.08x | CN¥-294.47 Million |
| 2023 | -18.18% | -3548.79% | 0.00x | 1.09x | CN¥-287.67 Million |
| 2024 | -26.20% | -5376.40% | 0.00x | 1.14x | CN¥-292.84 Million |
| 2025 | -18.94% | -1486.39% | 0.01x | 1.16x | CN¥-196.85 Million |
Industry Comparison
This section compares Shouyao Holdings (Beijing) Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,944,413,271
- Average return on equity (ROE) among peers: 42.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shouyao Holdings (Beijing) Co. Ltd. A (688197) | CN¥619.12 Million | -22.78% | 0.17x | $750.15 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $144.51 Million | -0.72% | 0.68x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $64.35 Million | 12.98% | 2.10x | $1.35 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $3.57 Million | 386.53% | 34.26x | $385.86 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $730.78 Million | -9.68% | 0.13x | $464.02 Million |
| Chengzhi Shareholding Co Ltd (000990) | $2.34 Billion | 3.13% | 0.67x | $1.28 Billion |
| Hualan Biological EngineeringInc (002007) | $4.44 Billion | 17.59% | 0.05x | $3.29 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $7.36 Billion | -10.11% | 0.16x | $1.08 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $10.90 Billion | -13.93% | 0.05x | $4.77 Billion |
| Baolingbao Biology Co Ltd (002286) | $238.05 Million | 18.81% | 2.12x | $487.64 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.22 Billion | 22.23% | 0.73x | $1.62 Billion |
About Shouyao Holdings (Beijing) Co. Ltd. A
Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of drugs in China. The company offers drugs for oncology indications, including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, breast cancer, ovarian cancer, thyroid cancer, leukemia, and diabetes. The company was founded in 2016 and is headquartered in Beijing, China.